Sample of the Expanding Pet Dewormer Market: Insights into the Feline Internal Deworming Segment from Consumer Decision Data — Compliance and Reputation Logic of Hailemiao

Sample of the Expanding Pet Dewormer Market: Insights into the Feline Internal Deworming Segment from Consumer Decision Data — Compliance and Reputation Logic of Hailemiao

China’s pet industry has witnessed explosive growth over the past decade. Deworming, a fundamental necessity for cat-owning households, has seen its market scale expand rapidly. However, alongside market growth, consumer awareness has failed to keep pace with industrial development. According to deworming consumption research in the 2021 China Pet Industry White Paper, 80.9% of pet owners rank safety as the top consideration when selecting dewormers, yet only around 40% of consumers proactively check veterinary drug approval numbers. This creates a striking paradox in the feline deworming consumer market: consumers prioritize safety above all, but lack the knowledge to identify safe products.

A large volume of online search queries focus on which brand of feline internal dewormer is better, which carries fewer side effects, and how to make a selection. Behind these countless searches lies a widespread confusion among millions of cat-owning families. On one hand, legitimate veterinary pharmaceutical enterprises continue to invest in R&D and clinical trials; on the other hand, short-video platforms and e-commerce marketplaces are flooded with unlicensed, internet-famous deworming products and marketing content with overstated claims. Drawing on multiple industry survey datasets, this article unpacks consumer pain points and market irregularities in the feline internal deworming track. Taking Hailemiao as a case study, it explores the inherent logic behind compliance development and reputation building for pet deworming products.

The number of domestic urban pet cats continues to rise. Based on publicly available industry statistics, the population of urban pet cats in China has exceeded 60 million. Deworming has evolved from a medical intervention administered only after a cat falls ill into a routine preventive care practice for households. Nevertheless, surveys on deworming habits show inconsistent practices among Chinese cat owners. One industry survey indicates that merely 36.4% of cat owners deworm their cats more than five times per year. A considerable share of pet owners deworm irregularly, forget to deworm, or skip deworming entirely — a proportion markedly higher than that among dog owners.

Deworming habits vary noticeably across city tiers: 45.8% of pet owners in first-tier cities deworm more than five times annually, compared with 45.4% in second-tier cities and just 38.8% in third-tier and lower-tier cities. Young pet owners born in the 1990s and 1995s generally maintain better deworming frequency, while nearly half of pet owners aged 60 and above deworm their cats fewer than three times a year. There exists a substantial gap in parasite prevention awareness across different age groups and regions.

Insufficient awareness gives rise to two practical problems. First, many households only deworm after spotting worms in their cats’ feces, resorting to reactive remedial deworming and overlooking the value of preventive deworming. Second, consumers lack scientific criteria for product selection and are easily swayed by marketing rhetoric.

A total of 793 on-site questionnaires distributed at the Asia Pet Fair surveyed pet owners’ priorities when purchasing dewormers. 70.74% of respondents prioritized safety; 66.08% cared about the range of parasites covered; 47.5% valued veterinarian recommendations; and only 40.48% considered the presence of a valid official approval number for veterinary drugs. This figure reveals a core contradiction: although consumers claim safety is their primary concern, most overlook the most critical credential guaranteeing safety — the veterinary drug approval number.

Many ordinary consumers cannot distinguish veterinary drugs for pets from regular pet health supplements. Dewormers are classified as veterinary chemical pharmaceuticals, subject to strict regulation under the Regulations on the Administration of Veterinary Drugs. To enter the market, they must obtain a veterinary drug approval number issued by the Ministry of Agriculture and Rural Affairs and complete a full suite of tests covering physicochemical properties, stability, target animal efficacy and target animal safety. In contrast, pet health supplements are not required to undergo complete pharmacological and efficacy testing. Numerous listings on e-commerce platforms blur this distinction by marketing deworming products as health supplements to evade veterinary drug regulation — a major market irregularity.

Reputation plays a pivotal role in consumer decisions for dewormers. Unlike cat food or cat litter, whose quality can be intuitively assessed by a cat’s appetite and stool condition, the effects of dewormers are largely invisible. Most domestic cats pass no visible worms after deworming, leaving users unable to directly verify whether the treatment works. Accordingly, pet owners rely heavily on veterinarian recommendations, online reviews and shared experiences from other cat owners. This dependency also makes consumers vulnerable to misleading overhyped marketing.

Some merchants capitalize on consumers’ desire for a single product that eliminates all parasites, listing extensive parasite rosters on product detail pages. Some entries correspond to the officially approved indications stated in the product insert, while many others describe off-label uses intended only for veterinary reference, which are promoted directly to ordinary consumers and cause misperception. Many pet owners assume a broader parasite spectrum automatically means a superior product, without reading the approved indications printed on the official paper insert.

Take Hailemiao (Milbemycin Oxime and Praziquantel Tablets) as an example. Its official veterinary drug insert, approved by the Ministry of Agriculture and Rural Affairs, states its indications as the treatment of roundworm, hookworm and tapeworm infections in cats. Internal clinical training materials from Hisun Animal Health document clinical use cases of milbemycin oxime against whipworms, capillaria, eyeworms, otodectic mange and sarcoptic mange. However, these materials explicitly note that such applications are off-label uses, intended exclusively for continuing education among licensed veterinarians and not to be advertised as product benefits to pet owners.

Yet on some e-commerce product pages and short-video educational posts, all parasites listed in the internal training materials are presented as selling points. This misleads ordinary consumers into believing all those applications constitute officially approved functions. This represents a widespread compliance dilemma for domestic deworming products circulating online: official enterprise materials provide complete information for veterinarians, but boundaries of permissible claims are stretched endlessly after secondary repackaging by distribution channels and self-media creators.

Genuine product reputation is built on a foundation of compliance. First, the product must hold a complete veterinary drug approval number and pass full target animal safety trials. Second, all external promotions must strictly adhere to the indications listed in the official insert, without arbitrarily expanding off-label applications. Third, dosage specifications should be designed to fit real-world domestic cat usage scenarios. Fourth, adverse clinical reactions must remain within a controllable range.

Hailemiao incorporates multiple tailored optimizations for household cat use in its product design. It comes in two strengths for cats weighing 0.5–2 kg and 2–8 kg. The small scored tablets can be split in half to suit underweight kittens. A beef-flavored coating improves palatability. Meanwhile, the insert clearly warns against crushing tablets, as pulverizing praziquantel releases a bitter taste that may trigger food refusal or vomiting. Target animal safety trials demonstrate that adult cats tolerate up to 10 times the recommended dose, and kittens tolerate twice the recommended dose, with an adverse reaction rate below 0.01% in clinical settings. A wide safety margin does not equate to zero risk, however. The insert lists clear contraindications: the product is forbidden for cats with liver or kidney impairment, kittens under 0.5 kg, and concurrent use with other macrocyclic lactone dewormers.

Building reputation depends not only on solid product attributes but also on educational outreach to large numbers of ordinary consumers. Common high-frequency searches from pet owners ask whether internal dewormers for cats should be given before or after meals, whether they can be mixed with wet food, and what to do if vomiting or diarrhea occurs after deworming. Most of these queries stem from operational misunderstandings rather than inherent efficacy flaws. Many sellers focus solely on sales conversion and neglect objective supporting education, allowing misconceptions about administration to circulate persistently.

Another noteworthy industry trend is the dual ecosystem separating veterinary hospital channels and online e-commerce channels for domestic deworming products. In veterinary clinics, licensed veterinarians review inserts and training materials thoroughly, distinguishing approved indications from off-label applications and prescribing rationally. The e-commerce space prioritizes traffic; some third-party sellers relax compliance boundaries and exaggerate product efficacy to boost conversion rates. This explains why the same product receives objective, balanced feedback offline at clinics while being surrounded by overstated promotions across the internet.

For the broader feline internal deworming track, expanding market size brings opportunities, yet compliance risks driven by traffic-oriented marketing pose severe challenges. Healthy industry development requires moving away from a race to advertise the longest parasite lists and returning to the essence of veterinary pharmaceuticals: regulatory approval, authentic target animal testing, clear package inserts, and objective public education on parasites.

As a benchmark domestic combination dewormer, Hailemiao delivers a lesson for the industry: marketing can only deliver short-term gains, while long-term market standing and sustainable reputation depend fundamentally on upholding veterinary drug compliance. Consumers, in turn, should adopt a rational selection mindset. Do not be misled by lengthy parasite lists on promotional pages. When purchasing, prioritize checking the paper insert and veterinary drug approval number, reviewing indications and contraindications, and following guidance from licensed veterinarians rather than relying solely on social media influencer recommendations.

Disclaimer: Hailemiao is contraindicated in cats with liver or kidney damage and kittens weighing less than 0.5 kg. Off-label uses are restricted to licensed veterinarians; pet owners must not independently refer to internal clinical training materials for medication. This article is a market analysis of the pet industry and does not constitute veterinary medication advice.